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Opinion statement
Imaging determines the optimal treatment for rectal cancer patients. High-resolution
magnetic resonance imaging (MRI) overcomes many of the known limitations of previous
methods. When performed in accordance with the recommended standards, MRI enables
accurate staging of both early and advanced rectal cancer, accurate response assessment,
the delineation of recurrent disease and planning surgical treatment in a safe and effective
manner. Tumour-related high-risk features with known adverse outcomes can be preoper-
atively identified and treated with neoadjuvant chemoradiotherapy. Further, MRI post-
treatment tumour response assessment using TRG grading system also predicts the likely
survival outcomes and in the future will be used to modify treatment further by stratifi-
cation into good and poor responders. There is a paucity of literature with validated
outcome data concerning use of diffusion-weighted imaging and positron emission
tomography (PET)/computed tomography (CT), and in the absence of any validated
methods and outcome data, their use in the initial assessment and restaging after
treatment is limited to research protocols. Combination MRI and CT is essential for distant
spread assessment and recurrent disease, and currently PET-CT is sometimes used in the
workup of patients with recurrent and metastatic disease.
Introduction
Preoperative assessment of tumour spread has become
essential for both early and locally advanced rectal can-
cer, response assessment to neoadjuvant chemoradio-
therapy (CRT) and resectability of recurrent disease. A
number of different imaging modalities have been used
to assess locoregional and distant tumour spread, with
magnetic resonance imaging (MRI) use predominating
for rectal cancer staging in the last 10 years. Nowadays,
for the majority of colorectal units, imaging assessment
of the primary tumour helps to determine the surgical
procedures and the necessity for preoperative treatment.
Implementation of bowel cancer screening programs
has increased the rate of patient identified with early
rectal cancers (ERC, defined as small early stage tu-
mours, T1/T2 and polyps) [1] who could potentially
benefit from adequately less aggressive surgical treat-
ment; imaging is mandatory for extramural spread as-
sessment and modern high-resolution methods can
even be used to define the degree of preservation of
submucosa and muscularis propria (provided that the
imaging quality complies with published standards) [2].
Specific imaging features of tumour aggressiveness prov-
en to predict outcomes such as magnetic resonance
(MR)-circumferential resection margin (CRM) [3] and
MR presence of extramural vascular invasion (EMVI) [4]
should also be taken into consideration when treatment
decisions are made in order to reduce risks of both local
and distant failure in rectal cancer patients.
Imaging is becoming necessary for tumour response
assessment when patients have completed neoadjuvant
therapy. Although histopathology remains the so-called
gold standard for evaluating tumour responsewithin the
final specimen, the opportunity to modify treatment
before definitive surgery takes place is missed. Thus,
preoperative identification of imaging complete re-
sponders (cr) will enable detection of patients who
could potentially undergo organ-preserving treatment
in the future and trials are underway to test the perfor-
mance of MRI in the identification and surveillance of
such patients. Conversely, preoperative detection of
poor responders may lead to further consolidation ther-
apy in order to reduce risks of local and distant failure.
Thus, the post-treatment assessment of response using
high-resolution MRI may in the future become a crucial
step in the management of patients with advanced rectal
cancer (TRIGGER: EudraCT Number 2015-003009-40).
Patients with locally recurrent rectal cancer form a
challenging group for cure due to limited treatment
option as CRT and surgery have usually been offered
previously. The importance of accurate imaging has
been recognised for these patients; a risk stratification
staging system is based on number and location of
pelvic compartments involved as identified on high-
resolution MRI. This method of assessment has been
shown to predict clinical and survival outcomes [5, 6•].
Imaging modalities involved in the local and distant
staging of rectal cancer are the following: endorectal
ultrasound (ERUS), MRI, computed tomography (CT)
and positron emission tomography (PET)/CT (a sum-
mary of different methods performance is listed in a
Table 1). Both ERUS and MRI are commonly recom-
mended for ERC staging, and there is also strong agree-
ment that MRI has become a required standard for
evaluating locally advanced disease particularly those
patients with potential CRM involvement. According
to NCCN (North America) [7]/NICE (UK) [8] guide-
lines, contrast-enhanced CT of the chest, abdomen and
pelvic should be offered to rectal cancer patients in order
to estimate distant spread of the disease [8]. Excessive
cost and time of a PET/CT scan limits its role to second
choice modality when CT or MRI results are ambiguous
in assessment of distant tumour spread. There are many
discussions regarding the use of PET/CT for evaluating
response to treatment; however, no consensus has been
found in performing PET/CT in this context. Neverthe-
less, a combination of different modalities, including
PET/CT, is almost always required in imaging of recur-
rent disease [9, 10].
ERUS
ERUS with the rigid probe has a number of imaging limitations including
inability to stage high, bulky and structuring tumours [11]. Use of either a 7–10-
MHz or flexible rigid ERUS ultrasound probe results in a small field of view
(FOV) that prevents assessment of tumour relationship to the potential
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circumferential margin (CRM). Inability to distinguish peritumoral fibrosis
from tumour spread limits use of ERUS in performing both primary and post-
CRT assessment of rectal cancer [12]. The crucial limitation of ERUS assessment
techniques is the limited views of the whole mesorectum and pelvis to exclude
tumour deposits, discontinuous vascular invasion and mesorectal fascia in-
volvement by tumour. Thus, disease beyond the immediate vicinity of the
primary tumour is impossible to evaluate using ERUS techniques and will
inevitably lead to understaging. According to the published meta-analysis,
ERUS does not perform any differently to either CT or MRI. However, this
analysis limited assessment to T and N staging only and did not take into
account the important prognostic variables that should also be assessed by
imaging, namely depth of extramural spread in millimetres, relationship of
tumour to the mesorectal fascia and extramural vascular invasion [13]. It has
been suggested that the published literature overestimates the performance of
ERUS in staging rectal cancer with median T stage accuracy of 69 % and N stage
Table 1. Advantages and disadvantages of different imaging methods.
Clinical
indication
Imaging modality
ERUS CT MRI PET/CT
Differentiation
between benign
polyps and
invasive
adenocarcinomas
+ Elastography appears promising – − No validated data –
Early rectal cancer
(T stage)
+ Only small T1sm1/2 tumours – + Enables visualisation of submucosa
and muscularis propria and
substaging of T1 and identification
of extramural disease
–
Advanced rectal
cancer (T stage)
– + + Allows T3 substaging + Only CT
component
N stage +/− Upper mesorectum and PSW
compartments are not in the
FOV
– + –
EMVI status − No validated data + + With greater sensitivity than
histopathology, especially after
chemoradiotherapy
+ Only CT
component
CRM status – – + (Distance from tumour to the
mesorectal fascia and
intersphincteric plane ≤1 is
considered as CRM involved)
–
Response
assessment
− No validated data – + (mr TRG predicts survival outcomes) +/−
Recurrence +/− Could be used in the limited
number of cases (limitations:
stenosing tumour, after APE or
exenteration)
– + Enable defining extend of the disease
within the pelvic compartments
+/−
+ accurate, +/− published data is controversial/application of the method is limited, – inaccurate/no validated data, PSW pelvic side wall
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of accuracy 65% for studies of 9300 subjects—again there is no published data
on the ability of ultrasound to stratify prognostic groups [14]. Despite many
expectations, ERUS has not proven to be effective in staging ERC, as preopera-
tive staging by these methods does not influence local recurrence or tumour-
specific survival [15]. The UK transanal excisional microsurgery (TEMS) registry
group reported that ERUS inaccurately staged rectal cancer in 44.8% out of 165
patients who underwent TEMS for ERC, and no significant difference was found
in the depth of TEM excision or R1 rate between the patients who underwent
ERUS before TEM and those who did not (p=0.73) [16]. As an assessment tool
for potentially significant polyps, ERUS with an elastography algorithm could
potentially be useful for differentiating malignant transformation within rectal
adenomas; a study by JER Waage et al. showed that strain elastography
could assess tissue hardness which enabled distinction between benign
adenomas vs invasive adenocarcinomas with 0.86 (0.66–0.96) specificity and
0.94 (0.88–0.97) accuracy when compared to final histopathology [17].
CT
The overall multidetector CT accuracy of T staging is around 86 % [18];
however, its sensitivity to predict relationship of the tumour to CRM is less than
50 % [19], making the method unreliable for clinical practice. Invasion of the
adjacent structuresmay be difficult to assess due to lack of fat plane between the
tumour, mesorectal fascia and adjacent structures anteriorly or in the lower
rectum.
For lymph node assessment, size is most commonly used CT criterion for
differentiating benign frommalignant lymph nodes; however, Bipat et al. meta-
analysis showed that CT had 55% sensitivity and 74% specificity for predicting
lymph node involvement in rectal cancer patients [13].
Nevertheless, published data suggests that such risk factors of tumour spread
as mucinous content and presence of EMVI could be identified on CT scans.
Heterogeneous enhancement and presence of areas of hypoattenuation are
more frequently identified within themucinous tumour vs non-mucinous [20].
It has been shown that CT allows visualisation of EMVI characterised by
nodularity and expansion of perirectal vessels [21], and in colon cancers, it can
be used to stratify good vs poor prognosis using depth of extramural spread of
95 mm as a definition for poor-risk tumours [22, 23].
MRI
MRI has become the optimal modality for the local staging of primary and
recurrent rectal cancer. There are several advantages over alternative techniques:
it enables to stratify tumours depending on the presence of several high-risk
features that are not limited to T and N stage (CRM and EMVI status, depth of
extramural invasion, presence of discontinuous extramural vascular spread/
deposits, presence of mucin and grade of tumour regression to preoperative
treatment). These have all been proven to influence disease-free and overall
survival rates in prospective multicentre studies. In recurrent rectal cancer, MRI
allows the delineation of tumour extent within the pelvic compartments, can
assess the pattern and mode of local recurrence and predict resectability of the
disease.
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Specific imaging parameters should be followed to achieve optimal results
of the MRI technique. Good quality high-resolution scan can be achieved if the
following technique criteria are satisfied (Table 2):
– Small FOV (not more than 160 mm) coronal, sagittal and axial slices
– Slice thickness (no more than 3 mm and voxel size less than 1.5)
– Correct scan plane alignment (perpendicular to the rectal wall at the level
of tumour advancing edge)0x(^list)
The voxel and FOV size increase will cause loss of resolution, so that
assessment of tumourmorphological characteristics becomes challenging.
Incorrect imaging plane incline usually leads to tumour overstaging.
Intravenous contrast to assess primary rectal cancer or recurrence is not
recommended as there is no evidence that its use improves accuracy or
gives additional prognostic staging information.
Primary Tumour Staging
T Stage
On high-resolution MRI scans, rectal wall anatomy is clearly depicted so depth
of tumour invasion can be correctly assessed. Not only is extension into the
mesorectum can be evaluated but also tumour spread within the layers of the
bowel wall. Therefore, MRI enables to identify patients with early rectal tu-
mours eligible for organ-sparing surgical treatment (local excision) and those
with high-risk tumours, when preoperative treatment is mandatory.
Early Rectal Cancer Staging
All rectal cancers apart from mucinous tumours demonstrate intermediate
signal intensity (SI), whereas the submucosal layer shows hyperintensity and
the muscularis propria (MP) low-intensity MR signal. The presence of a hyper-
intense stripe between the tumour and muscularis at the level of tumour
Table 2. Optimal MRI protocol for achieving high-resolution scans.
Sequence Sag TSE T2 Axial TSE T2 Axial TSE T2 high-resolution Cor TSE T2
TR 3961 4018 5362 5362
TE 125 80 100 100
TSE factor 23 20 16 16
FOV/RFOV 250/100 % 300/100 % 160/90 % 160/90 %
Slice thickness/gap 3/0.4 5/1 3/0.3 3/0.3
NSA 4 2 6 6
Matrix 320/512 256/512 256/256 256/256
Sat bands Ant/Sup None None None
Acquisition time 6.00 3.28 7.35 7.35
TR repetition time, TE echo time, TSE turbo spin echo, FOV field of view, RFOV reduced field of view
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advancing border (not the rolled edges) should be interpreted as full or partial
preservation of submucosa and indicates a likely T1sm1/2 at most; on the
contrary, absence of preserved submucosa but unaffected MP suggests T1sm3/
T2 (with partial invasion of the muscularis)—from the clinical point of view,
there is no need in differentiating these two stages (sm3/T2); if no macroscopic
invasion of the mesorectal fat is present and no low signal intensity line
identified between intermediate SI tumour and hyperintense mesorectal,
tumour should be staged as T2 (with full thickness of MP invasion)/T3a
(G1 mm tumour spread beyond the muscularis propria)—prognosis and
outcomes of patients with these T stages are no different, so their
distinction is unnecessary.
Advanced Rectal Cancer Staging
Macroscopic spread of tumour beyond the MP associated with worsen-
ing prognosis. Tumour spread G5 mm is associated with identical prog-
nosis as T2 tumours provided that there is no CRM involvement by
tumour. More advanced penetration into the mesorectum (T3c-d
disease) is associated with increasing rates of disease recurrence [24, 25].
Subclassification of T3 stage based on depth of tumour spread into the
mesorectum should be used, while MRI staging is performed as MRI has
been proven to be accurate in substaging T3 tumours with measured
equivalence to histopathology [26].
Circumferential Resection Margin
The outermost boundary of the mesorectum is defined by the mesorectal fascia
(MRF), which acts as a barrier to tumour spread and demarcates the CRM
during surgical excision. MRI has been proven to accurately identify potential
distance from tumour to CRMwithin 1mm, which is recognised by pathologist
as a clear margin [2, 27–29]. Results of the prospective MERCURY Study
showed that specificity of MRI for predicting pCRM is 92 % [30].
According to the TNM classification system, tumours invading the
mesorectal fascia are not T4—therefore, the predicted MRI CRM status must
always be reported in addition to the TNM. Ameasured distance of 1mmor less
from the primary tumour, tumour/vascular deposit, or invaded extramural
vessels to the MRF is one of the major prognostic factors for local recurrence,
poor disease-free survival and poor overall survival and should always be stated
in the MRI reports.
N Stage
Nodal staging is of questionable importance as a predictor for local recurrence
in patients receiving radical surgery for primary tumours; however, it still
should be assessed if local excision is considered. Some authors continue to
suggest using size criteria when determining the nature of mesorectal nodes;
however, there is no rational basis for this and all published pathology data
indicates that there is no relationship between the size of a lymph node and its
likelihood of malignancy [31]. In a histological survey of over 12,000 lymph
nodes from rectal cancer, specimens showed a considerable size overlap be-
tween normal, reactive and malignant nodes [31]. A prospective study where
nodes from in vivo MRI, MRI specimens and pathology specimens were
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matched showed that there was no useful size cutoff for predicting nodal status
[32]. Rather than size, it is the morphologic MR features such as presence of
heterogeneous MR signal and irregular borders of lymph node capsular that are
more reliable in differentiating nature of changes within nodes, and this has
been prospectively validated in several studies [32, 33].
EMVI
MRI EMVI defined as tumour signal within the vasculature outside the
muscularis propria has been proven to correlate with histopathology findings
[4] and survival outcomes [34]. On high-resolutionMRI, EMVI is demonstrated
as expansion of veins due to tumour signal present within them. It is an
independent risk factor for metastatic disease, and its presence in low rectal
cancers is also associated with a risk of CRM involvement and consequent local
recurrence [35, 36••].
Recurrent Rectal Cancer
Assessment of tumour resectability is one of the crucial things in recurrent rectal
cancer patients. Offering the best soft tissue contrast compared to the rest of the
available imaging modalities MRI enables evaluating relationship of recurrent
tumour to important landmarks—pelvic viscera, peritoneum, bones, nerves,
muscles, fasciae and ligaments. It has been highlighted that accurate delineation
of disease extent in relation to pelvic compartments is essential to plan themost
appropriate treatment for this group of patients [6•].
Tumour Response Assessment
After preoperative CRT, up to 30 % of patients will develop complete patho-
logical response defined as no tumour identified on the final histology exam-
inations. Modified Mandard grading system of tumour response was tested in
MERCURY study and has been proven to be a reliable tool for assessing tumour
response in rectal cancer [37••]. This grading scale is based on qualitative
assessment of intermediate signal vs low signal (the latter considered as fibrosis
and the former as residual disease) within the treated tumour. MR TRG 1–2 can
be described as low signal intensity scar or low density fibrosis with no evident
macroscopic intermediate signal intensity within it, mrTRG3 dominant fibrosis
outgrowing the tumour mass and mrTRG 4–5 predominantly intermediate
signal intensity with minimal or no signs of fibrosis. MERCURY experience
showed that patients with complete and near complete response (mrTRG 1–3)
have better prognosis, disease-free and overall survival compared to poor
responders [38].
Some studies suggest using DW-MRI in order to increase accuracy of tumour
response assessment and specificity for selecting patients eligible for deferral of
surgery trial, proposing that patients showing residual diffusion restriction on
high b value DW images should not be offered watch and wait policy [39, 40].
However, there is no published data proving the efficacy of applying DWI in
response assessment. Thus far, no publication has proven any added value of
DWI compared against mrTRG, ypT, ymrT, in assessing response, overall and
disease-free survival rates. A recent analysis has shown that only 32 % of
patients with imaging complete response (mrTRG1-3) would have been in-
cluded in the protocol if diffusion-weighted criteria had been applied, yet no
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difference in the rate of tumour regrowthwas identified amongst the 18 patients
from DWI group (33.3 %) compared to 56 patients in the mrTRG 1–3 group
(37%) (p=0.82) [41]. The data indicates that DW-MRI not only underestimates
patients with sustained complete response and does not improve specificity
compared with mrTRG.
PET/CT
The role of an imaging modality that provides a combination of functional
information (18F-FDG-PET) and morphologic information (CT) has not yet
been defined for rectal cancer staging. This method is not recommended in the
international standards of rectal cancer patients’management or guidelines for
local spread assessment [7]. It has been shown that PET/CT detects colonic
abnormalities larger than 13 mm in diameter with 90 % accuracy [42]; how-
ever, the specificity for differentiating hyperplastic benign polyps from primary
colorectal cancers is reported to be 43 % and thus the application of this
technique is uncertain [43].
The high cost and lower availability of PET are not the only disadvantages of
the method. It has been shown to be inaccurate in differentiating changes
within the mesorectal and pelvic lymph nodes [43, 44], it is also known to be
insensitive for assessing mucinous tumours and there is no data suggesting that
it could improve patient selection with complete response [45–47]. It is known
that up to 25 % of 18F-FDG-uptake occurs in metabolically active but non-
malignant tissues, such as granulation or inflammation [48, 49]. There are
several studies where response monitoring was performed and compared with
morphological response, and it has been demonstrated that the reduction in
SUVs was significantly greater in (histopathologically confirmed) responders
than in nonresponders [50, 51]; however, there is no consensus on the SUV
reduction rates needed to predict complete response.
A meta-analysis published by Huebner et al. included 11 studies and 577
patients showed that FDG-PET had 97 % sensitivity and 76 % for detecting
recurrent colorectal cancer [52]. However, Suga and colleagues reported that
prevalence of PET-positive cases in rectal cancer patients was higher with an
increase in carcinoembryonic antigen (CEA) levels (41% PET positivity for CEA
level of 5–10 vs 83 % with CEA level 950) [53]. Therefore, a rising CEA level,
equivocal findings on other imaging, should be considered an indication for
PET/CT in patients with known or suspected recurrent colorectal cancer[54••].
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